1,159 results on '"Andreone, Pietro"'
Search Results
152. Cognitive, neurological and psychiatric disorders occurring in Hepatitis C Virus infection
153. Hepatitis C virus‐associated indolent B‐cell lymphomas: A review on the role of the new direct antiviral agents therapy
154. Risk factors in acute diabetic foot syndrome: analysis of 75 consecutive patients referred to a tertiary center in Modena, Italy
155. Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease
156. SAT-517 - The sequential use of liver stiffness measurement and direct biomarkers of fibrosis is able to identify patients with severe non-alcoholic steatohepatitis
157. WED-260 - RESIST criteria accurately rule-out high-risk esophageal varices in patients with primary biliary cholangitis and compensated advanced chronic liver disease
158. OS-068 - Efficacy and safety at 96 weeks of bulevirtide 2 mg or 10 mg monotherapy for chronic hepatitis D: results from an interim analysis of a phase 3 randomized study
159. Mo1537 EFFICACY AND SAFETY OF BULEVIRTIDE MONOTHERAPY GIVEN AT 2 MG OR 10 MG DOSE LEVEL ONCE DAILY FOR TREATMENT OF CHRONIC HEPATITIS DELTA: WEEK 48 PRIMARY ENDPOINT RESULTS FROM A PHASE 3 RANDOMIZED, MULTICENTER, PARALLEL-DESIGN STUDY
160. Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial
161. Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B
162. Spleen Stiffness Measurements Predict the Risk of Hepatic Decompensation After Direct-Acting Antivirals in HCV Cirrhotic Patients.
163. Primary prophylaxis with nadolol in cirrhotic patients: Doppler patterns of splanchnic hemodynamics in good and poor responders
164. Ribavirin dose modification in treatment-naïve and previously treated patients who received telaprevir combination treatment: no impact on sustained virologic response in Phase 3 studies
165. Impact of insulin resistance on virologic response to a telaprevir-based regimen in patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: posthoc analysis of the REALIZE Phase III study
166. Efficacy and safety of telaprevir-based regimens in cirrhotic patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: subanalysis of the REALIZE Phase III study
167. Antibodies against Pegylated Interferon-alpha Affect Response to Treatment in Patients with Chronic Hepatitis C: 1753
168. The evolving clinical profile of chronic HBV infection. The Italian Master-B cohort: 923
169. High SVR24 rates with ritonavir-boosted danoprevir plus Peg-IFNα-2a (40KD)/RBV in HCV genotype 1 or 4 patients in the DAUPHINE study: 754
170. Hepatitis C recurrence after liver transplantation: do patients with mild disease need to be treated?: 207
171. Serum Pancreatic Enzyme Concentrations in Chronic Viral Liver Diseases
172. Telaprevir for Retreatment of HCV Infection
173. Recent news in the treatment of hepatitis B virus-related cryogobulinemic vasculitis
174. Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease
175. The time has come to look for metabolic dysfunction‐associated fatty liver disease in adult patients with type 1 Gaucher disease
176. S1126 Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) in Virally Suppressed Chronic Hepatitis B (CHB) Patients With Hepatic Impairment: Week 48 Results From a Phase 2 Open Label Study
177. Targeted pharmacotherapy for cardiovascular risk reduction in patients with diabetes undergoing liver transplantation: Author's reply
178. Pre-transplant diabetes predicts atherosclerotic vascular events and cardiovascular mortality in liver transplant recipients: a long-term follow-up study
179. The Effect of Liraglutide on β-Blockade for Preventing Variceal Bleeding: A Case Series
180. Safety and efficacy of switching to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with hepatic impairment: week 48 results from a phase 2 open label study
181. Pre-transplant diabetes independently predicts atherosclerotic vascular event and death due to cardiovascular disease in liver transplant recipients: a long term multicenter observational study
182. Diagnostic performance of PIVKA-II in patients with hepatocellular carcinoma
183. Hepatocellular carcinoma and liver transplant: beyond the Milan criteria and the risk of “short-blanket” syndrome
184. Spleen Stiffness Measurements Predict the Risk of Hepatic Decompensation After Direct-Acting Antivirals in HCV Cirrhotic Patients
185. Validation and refinement of PROSASH model using the neutrophil‐to‐lymphocyte ratio in patients with HCC receiving sorafenib
186. Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis
187. Chronic Spontaneous Urticaria: A Review of Pathological Mechanisms, Diagnosis, Clinical Management, and Treatment
188. Six score systems to evaluate candidates with advanced cirrhosis for orthotopic liver transplant: Which is the winner?
189. Thymalfasin: Clinical Pharmacology and Antiviral Applications
190. Role of Hepatitis B Virus Infection in the Prognosis After Hepatectomy for Hepatocellular Carcinoma in Patients With Cirrhosis: A Western Dual-Center Experience
191. Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-α2b: A Randomized Trial
192. Two yr mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant
193. Transcatheter Arterial Chemoembolization Therapy for Patients With Hepatocellular Carcinoma: A Case-Controlled Study
194. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation
195. Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes
196. Lack of Correlation Between Serum Anti-HBcore Detectability and Hepatocellular Carcinoma in Patients With HCV-Related Cirrhosis
197. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-[alpha]2b: a randomized trial
198. Sustained and Focused Hepatitis B Virus Nucleocapsid–Specific T-Cell Immunity in Liver Transplant Recipients Compared To Individuals With Chronic and Self-Limited Hepatitis B Virus Infection
199. Hepatocellular carcinoma appearance in patients with hepatitis C virus-related chronic liver disease 90 and 70 months after sustained virological response to interferon and ribavirin
200. Evolution of hepatitis C virus non-structural 5A gene in the progression of liver disease to hepatocellular carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.